Key facts
- This page summarizes Saiid Zarrabian's Form 4 filing for Kintara Therapeutics, Inc. (HURA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Dec 2021, 15:09.
Saiid Zarrabian - 06 Dec 2021 Form 4 Insider Report for Kintara Therapeutics, Inc. (HURA)
- Reporting relationship
- Head of Strategic Partnerships, Director
- Issuer ticker
- HURA
- Reported as of
- 06 Dec 2021
- Net transaction value
- +$31,316
- Reporting owner signature
- /s/ Saiid Zarrabian
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Saiid Zarrabian filed Form 4 for Kintara Therapeutics, Inc. (HURA) on 08 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$31,316.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KTRA
transaction
Common Stock
Purchase
- Transaction value
- $7,018
- Shares
- +11,891
- Change %
- +216%
- Price
- $0.5902*
- Shares after
- 17,391
- Date
- 06 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2
KTRA
transaction
Common Stock
Purchase
- Transaction value
- $24,298
- Shares
- +38,109
- Change %
- +219%
- Price
- $0.6376*
- Shares after
- 55,500
- Date
- 07 Dec 2021
- Ownership
- Direct
- Footnotes
- F2, F3
KTRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 590
- Date
- 06 Dec 2021
- Ownership
- By Child
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.5902 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Footnote F2
On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63115 to $0.6415 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
SEC remarks
Exhibit 24 - Power of Attorney